Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

John B. Christoforidis, Daniel J. DeAngelo, Donald J. D'Amico

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
JournalAmerican Journal of Ophthalmology
Volume135
Issue number3
DOIs
StatePublished - Mar 1 2003

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this